Dechra

Mirataz 20mg/g Transdermal Ointment for Cats

Name: Mirataz 20mg/g Transdermal Ointment for Cats
Availability: InStock

£46.79

Mirataz 20mg/g Transdermal ointment for cats is used for body weight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.

*Please note Mirataz is now available in 3g tubes and not 5g due to packaging changes*

Legal Category : POM-V

A valid veterinary prescription is required for purchase of this product.

Prescriptions

I understand a valid veterinary prescription is required for this prescription-only medicine *
I will provide my prescription by: *
Email prescription *

Please e-mail your prescription to [email protected]
Post prescription *

Please send to: Dr Nicola Endersby MRCVS, Cura, 4 Saxon Court, Bishop Auckland DL14 7UA

Vet will send directly *

Please ask your vet to e-mail your prescription to [email protected] with your name and order number as a reference. (You will receive your order number once you have completed your purchase) Please confirm your Vet Practice name below

Your vet practice: *
Prescription *

Please upload your prescription for this product.Max file size: 25 MBPermitted file types: jpg jpeg jpe gif png pdf
Animal name(s) *

Product total

Options total

Grand total

View POM Delivery & Returns

Secure Checkout with

Accredited Retailer

Mirataz 20mg/g Transdermal Ointment

The active ingredient Mirtazapine is absorbed through the skin of the ear into the bloodstream. The effects of mirtazapine on weight gain are complex and not fully understood. They include blocking some of the actions of serotonin and histamine, substances involved in the regulation of appetite, and an effect on levels of leptin, a hormone that controls hunger.

Use this product as directed by your veterinary surgeon. You should carefully read all product packaging and labels prior to use.

DEC-Miritaz-Vet-Tech-Brochure

The importance of treating poor appetite and weight loss resulting from chronic medical conditions in cats

Unintended feline weight loss may be associated with serious consequences;

A Low Body Condition Score (BCS) is linked to reduced survival across many disease states

Prolonged inadequate nutrition may be more detrimental to the patient than the primary disease process5

In diseased cats a change in production of inflammatory cytokines, catecholamines, cortisol, insulin and glucagon can trigger a hyper-metabolic state, characterised by protein catabolism, cachexia, insulin resistance, lipolysis and increased energy expenditure

Patients with cachexia may get into a negative nitrogen and energy balance, lose lean body mass and are at risk of developing malnutrition. Malnutrition can result in anaemia, hypoproteinaemia and reduced immune function, wound healing and organ function

Poor appetite is emotionally distressing to owners and is perceived as an indication of poor quality-of-life

Mirataz is the first licensed veterinary medicinal product for body weight gain in cats experiencing poor appetite.

The active ingredient, mirtazapine, addresses reduced appetite and induces significant weight gain in as little as 14 days.

This can allow for a swift response to initial symptoms – improving condition and wellbeing before you have a definitive diagnosis, alongside providing support to patients already receiving long term treatment.

Product Description

Mirataz 20mg/g Transdermal Ointment

The active ingredient Mirtazapine is absorbed through the skin of the ear into the bloodstream. The effects of mirtazapine on weight gain are complex and not fully understood. They include blocking some of the actions of serotonin and histamine, substances involved in the regulation of appetite, and an effect on levels of leptin, a hormone that controls hunger.

Use this product as directed by your veterinary surgeon. You should carefully read all product packaging and labels prior to use.

DEC-Miritaz-Vet-Tech-Brochure

The importance of treating poor appetite and weight loss resulting from chronic medical conditions in cats

Unintended feline weight loss may be associated with serious consequences;

A Low Body Condition Score (BCS) is linked to reduced survival across many disease states
Prolonged inadequate nutrition may be more detrimental to the patient than the primary disease process5
In diseased cats a change in production of inflammatory cytokines, catecholamines, cortisol, insulin and glucagon can trigger a hyper-metabolic state, characterised by protein catabolism, cachexia, insulin resistance, lipolysis and increased energy expenditure
Patients with cachexia may get into a negative nitrogen and energy balance, lose lean body mass and are at risk of developing malnutrition. Malnutrition can result in anaemia, hypoproteinaemia and reduced immune function, wound healing and organ function
Poor appetite is emotionally distressing to owners and is perceived as an indication of poor quality-of-life

Mirataz is the first licensed veterinary medicinal product for body weight gain in cats experiencing poor appetite.

The active ingredient, mirtazapine, addresses reduced appetite and induces significant weight gain in as little as 14 days.

This can allow for a swift response to initial symptoms – improving condition and wellbeing before you have a definitive diagnosis, alongside providing support to patients already receiving long term treatment.